Soins de santé

Perspectives thématiques sur la Conférence sur les produits thérapeutiques de 2026

nov. 11, 2025

Filmé lors de la 28e Conférence annuelle sur les produits thérapeutiques de TD Cowen, cet épisode de notre balado met en lumière les principaux thèmes liés aux produits thérapeutiques pour 2026. Les sujets discutés incluent un tournant pour la médecine génétique, l’innovation dans les conjugués anticorps-médicaments, le syndrome de Sjögren comme frontière inexplorée dans le domaine de l’immunologie et de l’inflammation, une renaissance pour la dermatologie et de nouvelles indications neurologiques et neuromusculaires orphelines. Nous nous attendons également à ce que les changements apportés au sein de la FDA entraînent de la volatilité, ce qui pourrait à la fois freiner l’innovation (réduction de personnel) ou la soutenir (accélération des approbations).

Les clients abonnés peuvent lire le rapport en entier, intitulé TD Cowen 28th Annual Therapeutics Conference Video - 2026 Thematic Outlook, sur le portail Une seule TD.

Mention juridique

Cet enregistrement ne doit pas être copié, distribué, publié ou reproduit, en tout ou en partie. Les renseignements contenus dans cet enregistrement ont été obtenus de sources accessibles au public, n’ont pas fait l’objet d’une vérification indépendante de la part de Valeurs Mobilières TD, pourraient ne pas être à jour, et Valeurs Mobilières TD n’est pas tenue de fournir des mises à jour ou des changements. Toutes les références aux cours et les prévisions du marché sont en date de l’enregistrement. Les points de vue et les opinions exprimés dans cet enregistrement ne sont pas nécessairement ceux de Valeurs Mobilières TD et peuvent différer de ceux d’autres services ou divisions de Valeurs Mobilières TD et de ses sociétés affiliées. Valeurs Mobilières TD ne fournit aucun conseil financier, économique, juridique, comptable ou fiscal ou de recommandations dans cet enregistrement. Les renseignements contenus dans cet enregistrement ne constituent pas des conseils de placement ni une offre d’achat ou de vente de titres ou de tout autre produit et ne doivent pas être utilisés pour évaluer une opération potentielle. Valeurs Mobilières TD et ses sociétés affiliées ne font aucune déclaration ou ne donnent aucune garantie, expresse ou implicite, quant à l’exactitude ou à l’exhaustivité des déclarations ou des renseignements contenus dans le présent enregistrement et, par conséquent, déclinent expressément toute responsabilité (y compris en cas de perte ou de dommage direct, indirect ou consécutif).

Tara Bancroft, PhD

Vice President, Health Care – Biotechnology Research Analyst, TD Cowen

Tara Bancroft, PhD
Vice President, Health Care – Biotechnology Research Analyst, TD Cowen

Biographie

Tara Bancroft, Ph.D. is a Vice President and senior equity research analyst on the biotechnology team at TD Cowen. Dr. Bancroft has over five years of equity research experience covering large-, mid-, and small-cap biotechnology stocks.

Prior to joining TD Cowen, Dr. Bancroft was an AVP at Piper Sandler (previously Piper Jaffray) for three years. Prior to Piper Sandler, Dr. Bancroft spent over four years as a postdoctoral researcher first at the La Jolla Institute for Immunology in San Diego where she identified optimized antigen epitopes for a re-formulated pertussis vaccine that went on to be published in Cellular Immunology and others. She then completed a postdoc at Fred Hutch in Seattle, where she discovered B-cell precursors to protective anti-HIV antibodies for the purpose of HIV vaccine design (which was published in JEM and others).

She received her Ph.D. from Yale University where she focused on discovering novel mechanisms involved in vascular injury and inflammation, resulting in numerous primary publications. She also completed a BS in biology at SUNY Buffalo, where she worked full-time in an oncology lab (with published work in JCP) and at an HIV clinical trial center.

Ritu Baral

Managing Director, Health Care – Biotechnology Research Analyst, TD Cowen

Ritu Baral
Managing Director, Health Care – Biotechnology Research Analyst, TD Cowen

Biographie

Ritu Baral joined TD Cowen in August 2014 as a senior biotechnology analyst and managing director. Ms. Baral has more than nineteen years of experience in biotechnology finance, including over sixteen years in biotechnology equity research. Her coverage has focused on rare diseases and neurology. From August 2006 until June 2014, she held a series of positions in biotechnology equity research at Canaccord Genuity, including senior analyst and managing director. Before that, Ms. Baral was an equity research associate at JMP Securities and a senior associate at the Trout Group. Previously, she was a research associate at Columbia University’s Department of Medicine, where she participated in neuroendocrine research focused on appetite and metabolism regulation, and completed graduate coursework in immunology.

Ms. Baral graduated with a BA in biological sciences from Barnard College. She is involved in a number of rare disease patient advocacy organizations, including as a board member of the Everylife Foundation for Rare Disease and the Industry Advisory Board of the National Tay-Sachs and Allied Diseases Foundation. She was previously on the board of directors of the Pulmonary Fibrosis Foundation.

Stacy Ku, PhD

Director, Health Care – Biotechnology Research Analyst, TD Cowen

Stacy Ku, PhD
Director, Health Care – Biotechnology Research Analyst, TD Cowen

Biographie

Stacy Ku is a director on TD Cowen’s biotechnology team. She joined TD Cowen in March 2018 after completing her Ph.D. in Neuroscience at Icahn School of Medicine at Mount Sinai.

Her NIH-funded fellowship research focused on the neurophysiological circuit interrogation of mechanisms underlying depression and stress. Her collaborative research experience also includes psychiatric and neurological disorders, spanning addiction, epilepsy, Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease.

Dr. Ku holds a Bachelor of Arts degree from Columbia University in Neuroscience and Behavior.

Joseph Thome, PhD

Managing Director, Health Care – Biotechnology Research Analyst, TD Cowen

Joseph Thome, PhD
Managing Director, Health Care – Biotechnology Research Analyst, TD Cowen

Biographie

Joseph Thome is a managing director and senior research analyst on TD Cowen’s biotechnology team. Dr. Thome was selected as a “Rising Star in Equity Research” by Business Insider in 2021 and the TD Cowen biotechnology team has consistently been among the top-ranked teams in the Greenwich Survey.

Prior to joining TD Cowen in March 2016, Dr. Thome was an NIH pre-doctoral research fellow at Columbia University, studying the compartmentalization and maintenance of the human T cell immune response from infancy into adulthood. His research has been published in several prestigious journals including Cell and Nature Medicine.

Dr. Thome received a BA with high honors in chemistry and biochemistry from Oberlin College and a Ph.D. in microbiology and immunology from Columbia University, where he was granted the Dean’s Award for Excellence in Research.

Yaron Werber, MD, MBA

Managing Director, Health Care – Biotechnology Research Analyst, TD Cowen

Yaron Werber, MD, MBA
Managing Director, Health Care – Biotechnology Research Analyst, TD Cowen

Biographie

Dr. Yaron Werber is a Managing Director and senior research analyst on TD Cowen’s biotechnology team. In this role, Dr. Werber is responsible for providing analysis on large-, mid-, and small-cap biotechnology stocks. Dr. Werber has 20+ years of experience as a research analyst in the financial services industry and has served as an executive in a public biotechnology company.

Prior to rejoining TD Cowen, Dr. Werber was a founding team member, chief business and financial officer, treasurer and secretary of Ovid Therapeutics, a biotechnology company focused on developing transformative drugs for orphan disorders of the brain. In this role, Dr. Werber established and was responsible for all financial planning and reporting, business development, strategy, operations/IT and investor and public relations and human resources functionality. Dr. Werber also led negotiations to secure several pipeline compounds including an innovative partnership with Takeda Pharmaceutical Company, a deal that expanded Ovid’s pipeline and pioneered a novel approach for partnering the focused expertise of small biotech with big pharma.

This deal was chosen by Scrip as a finalist for the 2017 Best Partnership Alliance Award. In addition, Dr. Werber oversaw all financing activities and led a $75 million Series B round in 2015 and Ovid’s $75 million IPO in 2017. In that capacity, Dr. Werber was selected as an “Emerging Pharma Leader” by Pharmaceutical Executive magazine in 2017.

Prior to joining Ovid, Dr. Werber worked at Citi from 2004 to 2015, where he most recently served as a managing director and head of U.S. healthcare and biotech equity research. During his tenure at Citi, Dr. Werber led a team that conducted in-depth analyses of life science companies at all stages of development, ranging from successful, profitable companies to recently public and privately held companies. Previously, Dr. Werber was a senior biotech analyst and vice president at SG Cowen Securities Corporation from 2001- 2004.

Dr. Werber has been awarded several accolades for performance and stock picking, he has been highly ranked by Institutional Investor magazine, has received awards from Starmine and was voted among the top five analysts in biotech in the Wall Street Journal’s “Best on the Street” Greenwich survey. He has frequently been featured as a guest on CNBC, Fox News, Bloomberg News and has been quoted in the Wall Street Journal, New York Times, Fortune, Forbes, Bloomberg thestreet.com and BioCentury.
Dr. Werber earned his B.S. in Biology from Tufts University, cum laude, and a combined M.D./MBA degree from Tufts University School of Medicine where he was a Terner Scholar.